## Edgar Filing: Spark Therapeutics, Inc. - Form 4

Spark Thera Form 4	apeutics, Inc.										
June 03, 20									OMB A	PPROVAL	
<b>FORN</b> Check t	UNITED	STATES		RITIES A			NGE	COMMISSIO		3235-0287 January 31,	
if no lor subject Section Form 4 Form 5 obligation may con <i>See</i> Inst 1(b).	16. or Filed pur <sup>ons</sup> Section 17(	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type	Responses)										
1. Name and Altschuler	Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol				g	5. Relationship of Reporting Person(s) to Issuer				
			Spark Therapeutics, Inc. [ONCE]				E]	(Check all applicable)			
(Last) (First) (Middle) 3737 MARKET STREET, SUITE 1300			3. Date of Earliest Transaction (Month/Day/Year) 06/01/2016					X_ Director 10% Owner Officer (give title Other (specify below) below)			
			4. If Amendment, Date Original Filed(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
(City)	(State)	(Zip)	Tab	la I Non I	Dorivotivo	Soouri	tion A	Person cquired, Disposed	of or Bonoficie	ally Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution any (Month/Da	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3,	ies (A) or of (D) 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	Perso	ons wh	o res	or indirectly. pond to the colle ained in this form		SEC 1474 (9-02)	

required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Der
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

## Edgar Filing: Spark Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year	r) (Instr. 8	() [ () ()	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 56.22	06/01/2016	А	(	6,000		<u>(1)</u>	05/31/2026	Common Stock	6,000

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh			
	Director	10% Owner	Officer	Other	
Altschuler Steven 3737 MARKET STREET SUITE 1300 PHILADELPHIA, PA 19104	х				
Signatures					
/s/ Joseph La Barge, as Attorne MD	06/03/2016				

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 100% of the shares vest on the one-year anniversary date of the grant

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(In